Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine

Consistent, high-level, vaccine-induced protection against human malaria has only been achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites. We report that the PfSPZ Vaccine--composed of attenuated, aseptic, purified, cryopreserved PfSPZ--was safe and well tolerated when administered four to six times intravenously (IV) to 40 adults. Zero of six subjects receiving five doses and three of nine subjects receiving four doses of 1.35 × 10(5) PfSPZ Vaccine and five of six nonvaccinated controls developed malaria after controlled human malaria infection (P = 0.015 in the five-dose group and P = 0.028 for overall, both versus controls). PfSPZ-specific antibody and T cell responses…

• UD
  U.S. Department of Defense
• HH
  Howard Hughes Medical Institute
• SB
  Small Business Innovation Research
• SC
  Southern Connecticut State University
• NI
  National Institutes of Health

  Awards: 4R44AI055229-08, 3R44AI055229-06S1, 5R44AI058499-05
• UN
  U.S. Navy
• NI
  National Institute of Allergy and Infectious Diseases
• NC
  NIH Clinical Center
• NM
  Naval Medical Research Center